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INTRODUCTION
Despite considerable progress in terms of 
diagnosis and treatment, the incidence of 
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ABSTRACT
Introduction: The incidence of Acute Kidney Injury is nowadays high in critically ill patients. Its etiology is 
multifactorial and a primary role is played by low cardiac output syndrome. Everything targeted to normalize 
cardiac output should increase the renal perfusion and abolish the secondary vasoconstriction. Levosimendan 
is a calcium sensitizer drug with inotropic properties that improves cardiac output and seems to increase renal 
blood flow. The aim of this meta-analysis was to evaluate the role of levosimendan in critically ill patients with 
or at risk of Acute Kidney Injury.
Methods: We performed a meta-analysis of  randomized controlled trials searching for trials that compared 
levosimendan with any comparator. The endpoints were the number of patients receiving Renal Replacement 
Therapy after randomization and the number of patients developing Acute Kidney Injury.
Results: Final analysis included 33 trials and 3,879 patients (2,024 levosimendan and 1,855 control). The 
overall analysis showed that the use of levosimendan was associated with a significant reduction in the risk 
of Renal Replacement Therapy (17 of 492 [3.5%] in the levosimendan group versus 37 of 427 [8.7%] in the 
control group, relative risk =0.52 [0.32 to 0.86], p for effect =0.01) and of Acute Kidney Injury (114 of 1,598 
[7.1%] in the levosimendan group versus 143 of 1,529 [9.4%] in the control arm, relative risk =0.79 [0.63 to 
0.99], p for effect =0.048). 
Conclusions: This meta-analysis suggests that the use of levosimendan is associated with a significant reduc-
tion of Renal Replacement Therapy in critically ill patients.
Keywords: levosimendan, acute kidney injury, critical care, renal replacement therapy. 
Acute Kidney Injury (AKI) remains high in 
critically ill patients. Interventions or med-
ications that can alter the clinical course of 
AKI and change the outcome of critically ill 
patients are scarce (1).
The etiology of acute renal failure in criti-
cally ill patients is multifactorial and a pri-
mary role is played by low cardiac output 
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syndrome and sepsis. The main determi-
nants of renal perfusion are cardiac output, 
blood pressure and blood volume. The kid-
neys normally receive 20-25% of the cardi-
ac output, although their total weight is less 
than 1% of total body weight. The decrease 
in cardiac output due to hypovolemia or 
cardiac dysfunction decreases renal perfu-
sion with direct and indirect mechanisms. 
Indeed, in addition to the reduction in re-
nal blood flow, activation of sympathetic 
nervous system, renin-angiotensin system 
and vasopressin secretion occur. Each in-
tervention targeted to normalize cardiac 
output and systemic perfusion should be 
able to increase the renal perfusion and 
abolish the secondary vasoconstriction. 
Levosimendan is a calcium sensitizer drug 
with inotropic properties (2). It also has va-
sodilating properties interacting with ATP-
sensitive K+channels of vascular smooth 
muscles cells. Levosimendan seems to re-
duce the release of pro-inflammatory cy-
tokines and to prevent the cardiomyocyte 
apoptosis. Therefore, it improves cardiac 
output and seems to increase renal blood 
flow by its vasodilating effects. Levosimen-
dan has already been associated with re-
duction of mortality in critically ill patients 
in a meta-analysis of randomized clinical 
trials, but its effects on renal function have 
never been systematically assessed (3).
The aim of this meta-analysis of random-
ized trials was to evaluate the role of levo-
simendan in critically ill patients with or at 
risk of AKI.
METHODS
We performed a systematic review and 
meta-analysis of randomized trials in ac-
cordance with the PRISMA (Preferred Re-
porting Items for Systematic reviews and 
Meta-Analyses) guidelines.
We searched for all randomized controlled 
trials that compared levosimendan with 
any pharmacological comparator or pla-
cebo in any clinical setting. Potentially eli-
gible trials were identified by searching the 
Cochrane central register, Embase, Scopus 
and Medline using a combination of subject 
headings and text words to identify ran-
domized controlled trials of levosimendan. 
The search was updated at January 2013. 
The full PubMed search strategy is available 
in the supplemental item S1. Searches were 
not restricted by language or publication 
status. To identify ongoing or unpublished 
trials, we searched the Clinical Trial Regis-
try. We also examined the reference lists of 
eligible trials and reviews together with the 
abstracts of international congresses. The 
following inclusion criteria were used for 
potentially relevant studies: random alloca-
tion to treatment and comparison of levosi-
mendan vs. control. There were no restric-
tions on age, drug’s dose or time of adminis-
tration. Exclusion criteria were overlapping 
publications, abstracts published before 
2010, oral administration of levosimendan, 
and lack of data on renal outcome. Two 
authors independently screened the search 
output to identify records of potentially eli-
gible trials, the full texts of which were re-
trieved and assessed for inclusion.
The primary endpoint was the number 
of patients receiving Renal Replacement 
Therapy (RRT) after randomization; the 
secondary endpoint was the number of pa-
tients developing AKI (as per author defi-
nition). We also collected data on serum 
peak creatinine and glomerular filtration 
rate. We contacted trial authors to obtain 
any missing outcome data. We extracted 
data on setting, dose of levosimendan, type 
of comparator, outcome data and length of 
follow up. We assessed the risk of bias asso-
ciated with the method of sequence genera-
tion, allocation concealment, blinding, and 
completeness of outcome data. We rated the 
risk of bias as being low, unclear, or high 
according to established criteria (4).
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Statistical analysis. For binary outcome 
we calculated the natural logarithm (ln) 
of risk ratios (RR) and its standard devia-
tion. We pooled these using the inverse 
variance method and a fixed effect model 
in case of low statistical inconsistency (I-
square≤25%) or with random-effect model 
(which better accommodates clinical and 
statistical variations) in case of moder-
ate or high statistical inconsistency (I-
square>25%). Weighted Mean Difference 
(WMD) and 95% confidence intervals were 
computed for continuous variables using 
the same methods as just described (4). To 
assess heterogeneity in results of individual 
studies, we used Cochran’s Q statistic and 
the  I-square  statistic (I-square>25% was 
considered as a threshold indicating sig-
nificant heterogeneity). Publication bias 
was assessed by visually inspecting funnel 
plots of the primary outcome, by analytical 
appraisal based on the Begg adjusted-rank 
correlation test and on Egger’s linear re-
gression test (a two-sided p value of 0.10 or 
less was regarded as significant).
Subgroup analyses were carried out to ex-
amine whether the effect of levosimendan 
on RRT varied by setting or type of infu-
sion. Sensitivity analyses were done to 
quantify the effect of levosimendan when 
restricted to trials with low risk of bias. We 
also investigated the influence of a single 
study on the overall risk estimate by se-
quentially removing study in order to test 
the robustness of the main results.
Statistical significance was set at the two-
tailed 0.05 level for hypothesis testing. 
Data analysis was performed using STATA 
11.0 Software (StataCorp LP, College Sta-
tion, TX, USA).
RESULTS
Characteristics of the included individual 
studies. Our search strategy identified 599 
unique publications, the titles and abstracts 
of which were screened for inclusion. The 
full text of 97 articles was retrieved, of 
which 33 (5-37) met the inclusion crite-
ria (Figure 1). Reasons for exclusion of the 
Figure 1 - Flow dia-
gram: selection process 
of included articles.
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Table 1 - Description of the 33 studies included in the meta-analysis.
Author Year Journal Control Setting Setting details
Al-Shawaf E 2006 J Cardiothorac Vasc Anesth Milrinone Cardiac surgery LCOS after CABG 
Alvarez J 2005 Rev Esp Anestesiol Reanim Dobutamine Cardiac surgery LCOS after cardiac surgery with CPB
Alvarez J 2006 Rev Esp Cardiol Dobutamine Cardiac surgery LCOS after cardiac surgery with CPB
Barisin S 2004 J Cardiovasc Pharmacol Placebo Cardiac surgery 20 min before surgery OPCABG
Baysal A 2013 J Cardiothorac Vasc Anesth Inotropes Cardiac surgery Cardiac surgery
Bonios MJ 2012 Int J Cardiol Dobutamine Cardiology HF (end stage)
Bragadottir G 2013 Crit Care Med Placebo Cardiac surgery Cardiac surgery
De Hert SG 2007 Anesth Analg Milrinone Cardiac surgery Cardiac surgery with CPB
Flevari P 2006 Am J Cardiol Placebo Cardiology HF (decompensated advanced)
Fuhrmann JT 2008 Crit Care Med Enoximone Cardiology Patients with acute myocardial infarction and car-
diogenic shock
Hou ZQ 2013 Cardiovasc Ther Placebo Cardiology LVEF<40%
Iyisoy A 2010 Turk J Med Sci Dobutamine Cardiology ADHF
Jarvela K 2008 J Cardiothorac Vasc Anesth Placebo Cardiac surgery After induction in aortic valve surgery with severe aortic valve stenosis and LV hypertrophy
Kurt IH 2010 Heart Vessels Standard of treatment Cardiology HF (NYHA class III-IV)
Lahtinen P 2011 Crit Care Med Placebo Cardiac surgery Heart valve surgery
Leppikangas H 2008 Acta Anaesthesiol Scand Placebo Vascular surgery Infrarenal abdominal aortic aneurysm
Levin R 2008 Rev Esp Cardiol Dobutamine Cardiac surgery LCOS after CABG 
Malfatto G 2012 J Cardiovasc Pharmacol Furosemide Cardiology HF (chronic)
Mebazaa A 2007 JAMA Dobutamine Cardiology ADHF
Moertl D 2005 Eur J Heart Fail Pge1 Cardiology HF (decompensated chronic)
Momeni M 2011 J Cardiothorac Vasc Anesth Milrinone Neonatal cardiac surgery Cardiac surgery
Morelli A 2005 Intensive Care Med Dobutamine Sepsis LV dysfunction post septic shock after 48 hours of 
conventional treatment
Morelli A 2010 Crit Care Dobutamine Septic shock
Nijhawan N 1999 J Cardiovasc Pharmacol Placebo Cardiac surgery ASA III-IV undergoing elective cardiac surgery
Packer M 2013 JACC Heart Fail Placebo and standard 
HF treatment
Cardiology Cardiology
Parissis JT 2006 Heart Placebo Cardiology HF (NYHA III-IV and LVEF≤30%)
Ricci Z 2012 Intensive Care Med Standard inotropic 
management
Pediatric cardiac surgery Cardiac surgery
Ristikankare A 2012 J Cardiothorac Vasc Anesth Placebo Cardiac surgery Cardiothoracic surgery
Slawsky MT 2000 Circulation Placebo Cardiology HF (NYHA class III-IV)
Tritapepe L 2009 Br J Anaesth Placebo Cardiac surgery CABG
Yilmaz MB 2007 Cardiovasc Drugs Ther Dobutamine Cardiology Worsening of HF 
Yontar OC 2010 Arq Bras Cardiol Dobutamine Cardiology HF (ischemic)
Zemljic G 2007 J Card Fail Nothing Cardiology HF (advanced, waiting for heart transplantation)
LCOS = low cardiac output syndrome; CABG = coronary artery bypass grafting; OPCABG = off-pump  coronary artery 
bypass grafting; CPB = cardiopulmonary bypass; HF =  heart failure; ADHF =  acute decompensated heart failure; NYHA 
= New York Heart Association; ASA = American Society of Anesthesiology Physical Classification System; LV = left ven-
tricle;  LVEF = left ventricular ejection fraction. 
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remaining articles are detailed in Figure 1. 
The list of the 97 major exclusions is avail-
able in the supplemental Table S1.
The 33 included trials randomized 3,879 
patients (2,024 to levosimendan and 1,855 
to control). Clinical heterogeneity was 
mostly due to setting, dose and control 
treatment (Tables 1 and 2). In details, 15 
studies used levosimendan in a cardiologi-
cal setting (decompensated heart failure, 
NYHA III-IV), 15 in cardiac surgery (two 
of these in pediatric patients), two stud-
ies were conducted in septic patients and 
one in vascular surgery patients. Twenty-
Table 2 - Description of levosimendan administration in the 33 studies included in the meta-analysis.




Lenght of levosimendan 
infusion (hours)
Al-Shawaf E 2006 12 0.1-0.2 24
Alvarez J 2005 12 0.2 24
Alvarez J 2006 12 0.2 24
Barisin S 2004 12 or 24
Baysal A 2013 6 0.1 24
Bonios MJ 2012 0.3 6 hours for 6 months
Bragadottir G 2013 12 0.1
De Hert SG 2007 0.1 19+4
Flevari P 2006 0.1 24
Fuhrmann JT 2008 12 0.1 for 50 min then 0.2 50 min- other 23 hours
Hou ZQ 2013 12 0.05 or 0.1 or 0.2 24
Iyisoy A 2010 12 0.1 24
Jarvela K 2008 0.2 24
Kurt IH 2010 12 0.1 24
Lahtinen P 2011 24 0.2 24
Leppikangas H 2008 24 0.2 24
Levin R 2008 10 0.1 24
Malfatto G 2012 0.1-0.4 24
Mebazaa A 2007 12 0.2 24
Moertl D 2005 12 0.1 24
Momeni M 2011 0.05 48
Morelli A 2005 0.2 24
Morelli A 2010 0.2 24
Nijhawan N 1999 18 or 26 0.2 or 0.3 6
Packer M 2013 12 (6 if under treatment with oth-
er inotropic or vasodilating drugs)
0.1 (0.2 if tolerated 0.1-0.05 
if not tolerated)
24
Parissis JT 2006 6 0.1-0.4 24
Ricci Z 2012 0.1 72
Ristikankare A 2012 12 0.2 24
Slawsky MT 2000 6 0.1-0.4 4-6
Tritapepe L 2009 24
Yilmaz MB 2007 0.1-0.2 24
Yontar OC 2010 0.3-0.6 0.1-0.2 24
Zemljic G 2007 12 0.1 24
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Figure 2 - Forest plot for the risk of Renal Replacement Therapy. The use of levosimendan was associated 
with a significant reduction in the risk of RRT (17 of 492 [3.5%] in the levosimendan group versus 37 
of 427 [8.7%] in the control group, RR=0.52, 95% CI 0.32 to 0.86, p for effect =0.01, p for heterogene-
ity=0.9, I-square=0%, with 13 studies included). 
RR = risk ratio; CI = confidence interval.  
three authors administered a loading dose 
and thirty-one used a continuous infusion 
(twenty-one of them following bolus). Dose 
varied between 0.3 and 0.6 mcg/kg as in-
travenous bolus and between 0.05 and 
0.4 mcg/kg/min as a continuous infusion. 
Thirteen studies (39% of all) used place-
bo as control while ten (30% of all) used 
dobutamine and 31% other comparators. 
Study quality appraisal indicated that stud-
ies were of variable quality (supplemental 
Table S2) with 13 (39%) of them having 
low risk of bias. 
Quantitative data synthesis. Overall analy-
sis on principal endpoint (Figure 2) showed 
that the use of levosimendan was associ-
ated with a significant reduction in the risk 
of RRT (17 of 492 [3.5%] in the levosi-
mendan group versus 37 of 427 [8.7%] in 
the control group, RR=0.52, 95% confi-
dence interval (CI) 0.32 to 0.86, p for effect 
=0.01, p for heterogeneity =0.9, I-square 
=0%, with 13 studies included). Visual 
inspection of funnel plots did not identify 
a skewed or asymmetrical shape (Figure 
3) and quantitative evaluation did not sug-
gest a presence of publication bias, as mea-
sured by the Begg test (p=0.3) and Egger 
test (p=0.9). All but one studies report-
ing RRT data administered levosimendan 
as bolus and the reduction in the need for 
RRT was confirmed in these 12 studies (17 
of 480 [3.5%] in the levosimendan group 
versus 37 of 415 [8.9%] in the control arm, 
 Levosimendan and acute renal failure
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Figure 3 - Funnel plot for the risk of Renal Replacement Therapy.  
RR = risk ratio; se = standard error. 
RR=0.52, 95% CI 0.31 to 0.86, p for effect 
=0.01, p for heterogeneity =0.9, I-square 
=0%). All but two studies reporting RRT 
data administered levosimendan in the 
perioperative period and the reduction in 
the need for RRT was confirmed in these 
11 studies (12 of 378 [3.2%] in the levo-
simendan group versus 29 of 363 [8%] in 
the control arm, RR=0.48, 95% CI 0.26 to 
0.89, p for effect=0.02, p for heterogene-
ity=0.9, I-square=0%). 
The analysis on secondary endpoints 
showed that the use of levosimendan was 
associated with a significant reduction in 
AKI risk (114 of 1,598 [7.1%] in the levosi-
mendan group versus 143 of 1,529 [9.4%] 
in the control arm, RR=0.79, 95% CI 0.63 
to 0.99, p for effect =0.048, p for heteroge-
neity =0.8, I-square =0%, with 19 stud-
ies included). This result was confirmed in 
the perioperative setting (39 of 411[9.5%] 
in the levosimendan arm versus 69 of 396 
[17%] in the control arm, RR=0.60, 95% 
CI 0.42 to 0.86, p for effect =0.005, p for 
heterogeneity =0.9, I-square =0%, with 
13 studies included).
Glomerular filtration rate was better after 
randomization in patients receiving levo-
simendan (WMD =8.08, 95% CI 3.35 to 
12.80, p for effect =0.001) in the 8 studies 
reporting it while no difference was found 
in peak serum creatinine values (WMD 
=-0.02, 95%  CI -0.11 to 0.07, p for effect 
=0.7) in the 15 studies reporting it. 
Sensitivity analyses considering only data 
from studies with low risk of bias con-
firmed a trend towards reduction in the 
risk of RRT (3 of 238 [1.3%] in the levosi-
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mendan group versus 10 of 177 [5.6%] in 
the control arm, RR=0.41, 95% CI 0.15 to 
1.12, p for effect =0.08, p for heterogene-
ity =0.9, I-square =0%, with 6 studies in-
cluded). When removing each single study 
from the meta-analysis to determine the in-
fluence of individual data sets to the pooled 
RRs, the corresponding pooled RRs were 
not altered (Figure 4) with the exception of 
the study of Baysal (9) (p=0.054 when it 
was removed).
DISCUSSION
We performed a comprehensive and updat-
ed review of randomized controlled trials to 
investigate the role of levosimendan in the 
prevention and treatment of AKI in criti-
cally ill patients. The most important result 
of this study is the reduction in the need 
for RRT in levosimendan-treated critically 
ill patients.
In critically ill patients sepsis, major sur-
gery (especially cardiac surgery) and acute 
decompensated heart failure are the most 
common triggers of AKI. The mainstay 
of prevention and treatment of AKI is the 
treatment of the cause of acute renal failure 
and withdrawal of nephrotoxic agents. If 
there are pre-renal or post-renal factors to 
be corrected, they must be identified. The 
optimization of hemodynamic conditions 
Figure 4 - Analysis of the influence of levosimendan versus any control on the overall risk of Renal Re-
placement Therapy. This figure shows the influence of individual studies on the summary Risk Ratio. The 
middle vertical axis indicates the overall RR and the two vertical axes represent the 95% CI. 
RR = risk ratio; CI = confidence interval. 
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should be the main goal of care and intra-
vascular volume must be monitored and 
maintained in the normal range. In addition 
to the optimization of hemodynamic sta-
tus and suspension of nephrotoxic agents 
no other pharmacological intervention has 
been shown to be effective in the preven-
tion and treatment of AKI and a recent web 
based survey suggested that the15 interven-
tions that might improve clinically relevant 
endpoints in critically ill patients with or at 
risk for AKI are supported by low levels of 
evidence.
Levosimendan [the (-) enantiomer of 
4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-
3-pyridazinyl) phenylhydrazonopropanedi-
nitrile] is a new calcium enhancer with cal-
cium-sensitizing activity. The mechanism 
of action that makes the levosimendan ef-
fective in preventing and treating kidney 
damage may be related to its beneficial ac-
tion on the normalization of hemodynamic 
conditions.
The main mechanism of action of this drug 
is an increase in affinity of troponin C for 
calcium and therefore the stabilization 
of the conformation of troponin C. This 
mechanism of action translates into ino-
tropic effect without determining increase 
intracellular cAMP or the intracellular cal-
cium concentration at the doses used in 
clinical practice. This mechanism leads to 
acceleration of actin-myosin cross-bridge 
formation rate and deceleration of the dis-
sociation rate. The binding becomes con-
siderably weaker during diastole, when the 
intracellular calcium concentration is low, 
and this has a beneficial effect on the relax-
ation of myocardial muscle cells, resulting 
in improvement of diastolic function. The 
positive inotropic effect is obtained without 
impairing ventricular relaxation or increas-
ing myocardial oxygen demand. 
Levosimendan also has ancillary actions 
that may be responsible for the beneficial 
actions on renal function. Levosimen-
dan indeed activates the opening of the 
ATP-sensitive sarcolemma K+ channels of 
smooth muscle cells and myocytes deter-
mining their hyperpolarization with con-
sequent vasodilatation, which may con-
tribute to augmentation of renal perfusion 
and depression of central venous pressure. 
Central venous pressure is an independent 
predictor of glomerular filtration rate in 
patients with congestive heart failure (38). 
An important mechanism of action of levo-
simendan on renal function may be linked 
to its ownership of venodilation, which re-
duces the renal congestion and increases 
renal perfusion pressure. Administration of 
levosimendan also entails a reduction of cir-
culating proinflammatory cytokines. This 
effect can be considered secondary to the 
inotropic and vasodilator properties of the 
drug, but may also result from the extracar-
diac downregulation of the synthesis of cy-
tokines through transcription factors (39). 
In addition, the administration of this drug 
induces significant reduction of soluble me-
diators of apoptosis, such as Fas and Fas li-
gand (40, 41). Still, levosimendan improves 
endothelial function through downregula-
tion of soluble cell adhesion molecules such 
as ICAM-1 and VCAM1 and regulates the 
mediators implicated in oxidative and ni-
trosative stress. Recent studies show that it 
can preserve organ function in acute and 
septic shock-induced myocardial depres-
sion via cooling down the oxidative burst of 
circulating cells (42, 43). Studies in animal 
models have yielded conflicting results re-
garding the effect of levosimendan on renal 
function. In fact, while in models of septic 
shock seem to outweigh the beneficial ef-
fects on hemodynamics, in animal models 
of ischemia reperfusion seems to prevail an 
effect of organ protection (44-49).
Bragadottir et al. (11) carried out a ran-
domized, placebo-controlled clinical trial 
over the effects of levosimendan on the re-
nal blood flow, the GFR, the renal oxygen 
44
T. Bove, et al.
Heart, Lung and Vessels. 2015, Vol. 7
consumption and the renal oxygen supply/
demand, in cardiac surgical setting. The 
main result of this paper is that levosimen-
dan induces renal vasodilation, preferen-
tially of pre-glomerular resistance vessels, 
increasing both renal blood flow and glo-
merular filtration rate, without impairing 
renal oxygen demand/supply relationship 
as demonstrated by the lack of effect on re-
nal oxygen extraction. The careful analysis 
of the literature has identified 33 studies 
that evaluated the effect of levosimendan 
on renal function performed on critically ill 
patients in four different settings: cardiol-
ogy (16 studies), cardiac surgery (15 stud-
ies), vascular surgery (1 study) and sepsis 
(2 studies). Although in most of them the 
impact of levosimendan on renal function 
was not the pre-planned primary outcome 
and most of them are individually statisti-
cally underpowered, many of them suggest-
ed a trend of benefit on renal function, and 
the pooled data analysis of 4,082 patients 
included in the meta-analysis suggests a 
beneficial effect of levosimendan on renal 
function including glomerular filtration 
rate, AKI as per author definition and RRT 
with sensitivity analyses confirming the va-
lidity of our findings.
The findings of our manuscript could be 
compared to those of three other papers. 
In a previous meta-analysis Landoni et al. 
highlighted the beneficial effects of levosi-
mendan in critically ill patients (3). How-
ever, the authors did not investigate the re-
nal outcomes and the search was updated at 
November 2010. A more recent meta-anal-
ysis (50) suggested for the first time a ben-
eficial effect of levosimendan on AKI, but 
the study was limited to the cardiac surgery 
setting and to 529 patients. A recent con-
sensus report (51) suggested a beneficial ef-
fect of levosimendan on renal outcomes but 
it was a systematic review of the literature 
without a meta-analytic approach.
The main limitation of the present meta-
analysis is that several included RCTs were 
of suboptimal quality. Furthermore, tradi-
tional limitations of meta-analyses due to 
variations in the treatment regimens, in 
populations or major subgroups within tri-
als, and in the conduct of the trials apply to 
this study. On top of that, great variability 
of clinical setting and a relative small num-
ber of studies analyzed for primary end 
point (RRT) should be acknowledged.
CONCLUSION
This meta-analysis shows that the use of 
levosimendan is associated with a signifi-
cant reduction in incidence of RRT in criti-
cally ill patients. Since meta-analyses are 
hypothesis generating, large multicenter, 
randomized, placebo-control clinical trials 
designed to assess the role of levosimendan 
in the treatment of acute renal failure in 
critically ill patients are warranted.
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